Pharsight

Drugs that contain Rasagiline Mesylate

1. Azilect patents expiration

AZILECT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5532415 TEVA R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
Jul, 2013

(10 years ago)

US7815942 TEVA Rasagiline formulations of improved content uniformity
Aug, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6126968 TEVA Stable compositions containing N-propargyl-1-aminoindan
Sep, 2016

(7 years ago)

US5453446 TEVA Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
Feb, 2017

(7 years ago)

US7572834 TEVA Rasagiline formulations and processes for their preparation
Dec, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-685) May 29, 2017

Market Authorisation Date: 16 May, 2006

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

More Information on Dosage

AZILECT family patents

Family Patents